Replimune/$REPL
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
- Ticker
- $REPL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 465
- Headquarters
- Woburn, United States
- Website
- www.replimune.com
Replimune Metrics
BasicAdvanced
$1.5B
-
-$3.15
0.90
-
Price and volume
Market cap
$1.5B
Beta
0.9
52-week high
$15.89
52-week low
$1.50
Average daily volume
6.5M
Financial strength
Current ratio
5.228
Quick ratio
5.085
Long term debt to equity
102.168
Total debt to equity
105.992
Interest coverage (TTM)
-29.78%
Profitability
EBITDA (TTM)
-290.44
Effective tax rate (TTM)
0.19%
Management effectiveness
Return on assets (TTM)
-51.30%
Return on equity (TTM)
-134.29%
Valuation
Price to book
12.56
Price to tangible book (TTM)
12.56
Price to free cash flow (TTM)
-5.302
Free cash flow yield (TTM)
-18.86%
Free cash flow per share (TTM)
-2.98
Growth
Earnings per share change (TTM)
-12.40%
3-year earnings per share growth (CAGR)
2.10%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL
Newsfile Corp1 week ago
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL
Business Wire2 weeks ago
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.